Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
TCL-1A Double Nickase Plasmid (h): sc-402028-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TCL-1A Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- TCL-1A Double Nickase Plasmid (h) and TCL-1A Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting TCL1A. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TCL-1A Antibody (A-6): sc-393436
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TCL-1A Double Nickase Plasmid (h) | sc-402028-NIC | 20 µg | $410.00 | |||
TCL-1A Double Nickase Plasmid (h2) | sc-402028-NIC-2 | 20 µg | $410.00 |
TCL1A encodes the oncogenic adaptor protein TCL-1A, a key modulator of AKT/PKB signaling that enhances PI3K–AKT pathway output and supports cell growth, survival, and metabolic programs. TCL-1A is most prominently expressed in lymphoid lineages during development and can influence B- and T-cell maturation by tuning signal transduction thresholds. Dysregulated TCL1A expression has been linked to lymphoproliferative phenotypes and is frequently studied in the context of hematologic malignancies where aberrant AKT activation and altered apoptotic control are common. As a signaling cofactor, TCL-1A provides a mechanistic entry point for probing how pathway amplification impacts transcriptional states, stress responses, and transformation-associated cellular behaviors.
TCL-1A Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the TCL1A locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within TCL1A. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt TCL1A function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of TCL1A-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.